AR029941A1 - Compuestos utiles para elevar el nivel plasmatico de la hormona del crecimiento y las composiciones farmaceuticas que las contienen - Google Patents

Compuestos utiles para elevar el nivel plasmatico de la hormona del crecimiento y las composiciones farmaceuticas que las contienen

Info

Publication number
AR029941A1
AR029941A1 ARP010102827A ARP010102827A AR029941A1 AR 029941 A1 AR029941 A1 AR 029941A1 AR P010102827 A ARP010102827 A AR P010102827A AR P010102827 A ARP010102827 A AR P010102827A AR 029941 A1 AR029941 A1 AR 029941A1
Authority
AR
Argentina
Prior art keywords
growth hormone
elevate
pharmaceutical compositions
compositions containing
useful compounds
Prior art date
Application number
ARP010102827A
Other languages
English (en)
Spanish (es)
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of AR029941A1 publication Critical patent/AR029941A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0212—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -N-C-N-C(=0)-, e.g. retro-inverso peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Surgery (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
ARP010102827A 2000-06-13 2001-06-13 Compuestos utiles para elevar el nivel plasmatico de la hormona del crecimiento y las composiciones farmaceuticas que las contienen AR029941A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21132600P 2000-06-13 2000-06-13
US23492800P 2000-09-26 2000-09-26

Publications (1)

Publication Number Publication Date
AR029941A1 true AR029941A1 (es) 2003-07-23

Family

ID=26906052

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010102827A AR029941A1 (es) 2000-06-13 2001-06-13 Compuestos utiles para elevar el nivel plasmatico de la hormona del crecimiento y las composiciones farmaceuticas que las contienen

Country Status (29)

Country Link
US (2) US6861409B2 (enExample)
EP (1) EP1289951B1 (enExample)
JP (2) JP3522265B2 (enExample)
KR (1) KR100825109B1 (enExample)
CN (1) CN1232507C (enExample)
AR (1) AR029941A1 (enExample)
AT (3) ATE302181T1 (enExample)
AU (2) AU6606601A (enExample)
BG (3) BG66130B1 (enExample)
BR (1) BRPI0111591B8 (enExample)
CA (1) CA2407659C (enExample)
CY (2) CY1107710T1 (enExample)
CZ (2) CZ303173B6 (enExample)
DE (3) DE60130025T2 (enExample)
DK (3) DK1289951T3 (enExample)
ES (3) ES2250416T3 (enExample)
FR (1) FR19C1044I2 (enExample)
HU (1) HU229233B1 (enExample)
IL (2) IL153067A0 (enExample)
MX (1) MXPA02011899A (enExample)
NL (1) NL300999I2 (enExample)
NO (1) NO323873B1 (enExample)
NZ (1) NZ522280A (enExample)
PL (1) PL216676B1 (enExample)
PT (2) PT1344773E (enExample)
RU (1) RU2270198C2 (enExample)
SK (1) SK287169B6 (enExample)
TW (2) TWI305529B (enExample)
WO (1) WO2001096300A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE302181T1 (de) * 2000-06-13 2005-09-15 Zentaris Gmbh Verbindungen zur stimulation der sekretion von wachstumshormonen
CU23157A1 (es) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US7034050B2 (en) * 2004-04-28 2006-04-25 Romano Deghenghi Pseudopeptides growth hormone secretagogues
RU2416612C9 (ru) * 2005-07-22 2012-03-27 Ипсен Фарма С.А.С. Стимуляторы секреции гормона роста
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
GB0603295D0 (en) * 2006-02-18 2006-03-29 Ardana Bioscience Ltd Methods and kits
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
US7763707B2 (en) * 2006-03-13 2010-07-27 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation
ES2602789T3 (es) 2007-02-09 2017-02-22 Ocera Therapeutics, Inc. Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina
EP2103602A1 (en) 2008-03-17 2009-09-23 AEterna Zentaris GmbH Novel 1,2,4-triazole derivatives and process of manufacturing thereof
US8431642B2 (en) * 2008-06-09 2013-04-30 Exxonmobil Chemical Patents Inc. Polyolefin adhesive compositions and articles made therefrom
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
US10300101B2 (en) 2012-09-19 2019-05-28 Quality IP Holdings, LLC Methods and compositions for enhancing or maintaining fertility
US8747922B2 (en) 2012-09-19 2014-06-10 Quality Ip Holdings, Inc. Methods and compositions for increasing sex steroids and growth hormones
US9198889B2 (en) 2012-09-19 2015-12-01 Quality IP Holdings, LLC Methods for treating post-traumatic stress disorder
US8747921B2 (en) 2012-09-19 2014-06-10 Quality Ip Holdings, Inc. Methods for improving health in humans
US10292957B2 (en) 2012-09-20 2019-05-21 Quality IP Holdings, LLC Compositions and methods for treating fibromyalgia
US9066953B2 (en) 2012-09-20 2015-06-30 Quality IP Holdings, LLC Methods for increasing endurance and fat metabolism in humans
US8747923B2 (en) 2012-09-20 2014-06-10 Quality Ip Holdings, Inc. Methods for improving health in canines
US8715752B2 (en) 2012-09-20 2014-05-06 Quality Ip Holdings, Inc. Compositions for increasing human growth hormone levels
CA2889499C (en) 2012-10-24 2019-09-10 Daiichi Sankyo Company, Limited Growth hormone secretagogue receptor agonists for treating amyotrophic lateral sclerosis
CN105330720A (zh) * 2014-06-06 2016-02-17 深圳翰宇药业股份有限公司 一种制备马昔瑞林的方法
CN108348501A (zh) * 2015-09-21 2018-07-31 埃莫奈特药业有限责任公司 检测和治疗生长激素缺乏症
US10894072B2 (en) 2017-02-13 2021-01-19 IP Quality Holdings, LLC Compositions and methods for treating fibromyalgia
US10288629B1 (en) 2017-12-19 2019-05-14 Aeterna Zentaris, Inc. Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
CN114258492A (zh) 2020-07-22 2022-03-29 阿特纳赞塔里斯有限公司 一种通过使用马昔瑞林诊断儿科患者中生长激素缺乏症的筛选方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880778A (en) * 1986-05-12 1989-11-14 Eastman Kodak Company Combinations having synergistic growth hormone releasing activity and methods for use thereof
AU637316B2 (en) * 1988-01-28 1993-05-27 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
WO1995014666A1 (en) * 1993-11-24 1995-06-01 Merck & Co., Inc. Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US6025471A (en) * 1998-06-03 2000-02-15 Deghenghi; Romano Diazaspiro, azepino and azabicyclo therapeutic peptides
ATE302181T1 (de) * 2000-06-13 2005-09-15 Zentaris Gmbh Verbindungen zur stimulation der sekretion von wachstumshormonen

Also Published As

Publication number Publication date
US6861409B2 (en) 2005-03-01
CA2407659C (en) 2010-11-09
CY1107710T1 (el) 2013-04-18
ES2292900T3 (es) 2008-03-16
BG66130B1 (bg) 2011-06-30
BG110708A (en) 2010-12-30
HU229233B1 (en) 2013-09-30
DK1524272T3 (da) 2007-09-03
HUP0302026A3 (en) 2009-01-28
CN1232507C (zh) 2005-12-21
PL216676B1 (pl) 2014-05-30
DK1344773T3 (da) 2007-12-27
DE60112753D1 (de) 2005-09-22
NO20025893D0 (no) 2002-12-09
BG107379A (bg) 2003-09-30
WO2001096300A1 (en) 2001-12-20
DK1289951T3 (da) 2005-12-19
DE60130025T2 (de) 2008-05-15
CZ20024095A3 (cs) 2003-05-14
EP1289951A1 (en) 2003-03-12
US7297681B2 (en) 2007-11-20
JP4932132B2 (ja) 2012-05-16
DE60128494D1 (de) 2007-06-28
US20040229823A1 (en) 2004-11-18
DE60128494T2 (de) 2008-01-17
NL300999I2 (nl) 2019-08-28
DE60112753T2 (de) 2006-06-29
JP2004503536A (ja) 2004-02-05
BG110771A (bg) 2011-03-31
ES2288724T3 (es) 2008-01-16
ATE302181T1 (de) 2005-09-15
NZ522280A (en) 2004-09-24
BR0111591A (pt) 2003-05-06
TW200831076A (en) 2008-08-01
MXPA02011899A (es) 2003-04-22
PL363081A1 (en) 2004-11-15
FR19C1044I2 (fr) 2020-07-24
HK1054224A1 (en) 2003-11-21
KR100825109B1 (ko) 2008-04-25
SK287169B6 (sk) 2010-02-08
TWI305529B (en) 2009-01-21
PT1344773E (pt) 2007-11-27
JP2003335752A (ja) 2003-11-28
JP3522265B2 (ja) 2004-04-26
BG66217B1 (bg) 2012-05-31
IL153067A0 (en) 2003-06-24
DE60130025D1 (de) 2007-09-27
AU2001266066B2 (en) 2005-06-30
BG66216B1 (bg) 2012-05-31
BRPI0111591B8 (pt) 2021-05-25
EP1289951B1 (en) 2005-08-17
NO323873B1 (no) 2007-07-16
PT1524272E (pt) 2007-07-25
ATE362472T1 (de) 2007-06-15
US20020165343A1 (en) 2002-11-07
IL153067A (en) 2010-05-31
NO20025893L (no) 2003-02-10
CY1107793T1 (el) 2013-06-19
NL300999I1 (nl) 2019-07-17
AU6606601A (en) 2001-12-24
ATE370119T1 (de) 2007-09-15
CZ303173B6 (cs) 2012-05-16
FR19C1044I1 (enExample) 2019-09-08
ES2250416T3 (es) 2006-04-16
CA2407659A1 (en) 2001-12-20
HUP0302026A2 (hu) 2003-09-29
KR20030007889A (ko) 2003-01-23
CN1431998A (zh) 2003-07-23
SK17562002A3 (sk) 2003-05-02
BR0111591B1 (pt) 2014-02-04
CZ305279B6 (cs) 2015-07-15
RU2270198C2 (ru) 2006-02-20

Similar Documents

Publication Publication Date Title
UY26186A1 (es) Inhibidores de metaloproteasas
YU97902A (sh) Ciklopentanoindoli, smeše koje sadrže takva jedinjenja i metodi lečenja
AR013873A1 (es) Una composicion que comprende derivados de tetralina y factores ico neurologicos para estimular el crecimiento de neuritas en celulas nerviosas
BG110708A (en) MEANS THAT ENOUGH THE GROWTH HORMONE SECRET
PA8523001A1 (es) Derivados de la 3-indolil-4-fenil-1h-pirrol-2,5-diona como inhibidores de glicogeno sintasa quinasa-3b
PE20050123A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas y composiciones farmaceuticas que los incluyen
ES2074867T3 (es) Derivados de quinazolina para potenciar la actividad antitumoral.
UY27069A1 (es) Activadores de glucocinasa del tipo isoindolin-1-ona
CY1105748T1 (el) Χρηση της ριλουζολης συνδυασμενης με καταλληλα εκδοχα και προσθετες ουσιες για τη θεραπεια ασθενειων που χαρακτηριζονται απο υπερβολικο πολλαπλασιασμο των κερατινοκυτταρων ιδιαιτερως της νευροδερματιτιδας και της ψωριασης
UY27419A1 (es) Formulaciones en combinación de derivados de 1,4-benzotiepina-1,1-dioxido con otras sustancias activas, y su utilización.
UY28536A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
AR012193A1 (es) Nuevas combinaciones terapeuticas
CY1110644T1 (el) 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις
MX9400070A (es) Compuestos heterociclicos, un procedimiento para prepararlos, su uso y composiciones farmaceuticas que los contienen.
NO984950L (no) Forbindelser med veksthormonfrigj°rende egenskaper
ES2104821T3 (es) Cetoacidos que contienen quinoleina como antagonistas de leucotrienos.
UY26895A1 (es) Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2
AR026209A1 (es) Compuestos monociclicos basicos con accion nk-2 antagonista, procesos de fabricacion y formulas que los contienen
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
ES2185837T3 (es) Utilizacion de derivados de teofilina para el tratamiento y la profilaxis de las enfermedades de choque, nuevos compuestos de xantina y procedimientos para su produccion.
AR026004A1 (es) Pirroles substituidos.
ES2136198T3 (es) Composiciones rectales que contienen odansetron en forma de su base libre.
ATE295838T1 (de) Benzimidazolderivate zur behandlung von mit mikroglia-aktivierung assoziierten erkrankungen wie inflammatorische, allergische, infektiöse oder autoimmune erkrankungen
ES2055440T3 (es) Derivados del acido quinurenico, su preparacion y composiciones farmaceuticas que los contienen.
ES2049703T1 (es) Derivados de acidos biliares sulfurados.

Legal Events

Date Code Title Description
FG Grant, registration